Anna Golebiewska

The paper identifies impaired monocyte states and trajectories in glioblastoma patients through immune profiling, revealing systemic immune reprogramming and potential therapeutic targets.

This study develops and tests a dual strategy using NaMiX and TriKE to enhance NK cell cytotoxicity against PDAC, showing improved tumor cell killing in vitro and in humanized mouse models.

This study develops humanized glioblastoma PDOX models to study tumor-immune interactions and test immunotherapies in a human context.

This study integrates multi-omics and functional drug screening in patient-derived organoids to identify personalized therapeutic vulnerabilities in adult high-grade gliomas, finding distinct drug responses in IDH1 mutant and MYCN-amplified tumors.

This study identifies genetic changes in IDH-mutant gliomas that correlate with treatment response and tumor evolution using longitudinal genomic data from 206 patient samples.

This study shows that adenoviral delivery of CIITA enhances T-cell mediated killing of glioblastoma organoids, with some MHC-II-independent immune responses observed.

This study analyzes the epigenetic evolution of IDH1-mutant and IDH1-wildtype gliomas under treatment, showing IDHmut tumors undergo epigenomic changes resembling IDHwt tumors, with implications for treatment strategies.

The paper introduces a drug sensitivity prediction system using a 47-gene expression profile derived from transcriptomic analysis, validated with independent datasets and showing high concordance with observed drug responses.